The Mechanistic Bridge: PRKN Dephosphorylation and Mitochondrial Stress

Cellular survival depends on the rapid elimination of dysfunctional mitochondria. When mitochondrial membrane potential collapses, cellular sensors trigger quality control programs to avert toxic cytosolic spillover. PRKN dephosphorylation represents a vital regulatory node that fine-tunes this mitochondrial triage. Specifically, PTEN-induced kinase 1 (PINK1) accumulates on the outer mitochondrial membrane upon depolarization. PINK1 then phosphorylates ubiquitin and recruits the cytosolic E3 ubiquitin ligase Parkin, encoded by the PRKN gene. Consequently, activated Parkin ubiquitinates mitochondrial surface substrates to license selective autophagic clearance, known as mitophagy.

However, damaged mitochondria do not merely provoke safe waste disposal; they also initiate inflammatory cell demise. Recent structural insights reveal that the phosphatase PTEN-L directly counteracts PINK1 activity by removing phosphate groups from Parkin. This precise dephosphorylation arrests the catalytic cycle of the ligase. Furthermore, this enzymatic arrest prevents downstream organelle degradation. Meanwhile, researchers discovered that this dephosphorylation event restrains the cellular transition toward programmed lytic death. Therefore, the dephosphorylation of PRKN functions as an active molecular gatekeeper that coordinates survival mechanisms against inflammatory tissue destruction.

The PINK1-PRKN Axis and Execution of Pyroptotic Cell Death

Historically, medical science categorized pyroptosis as an immune response driven exclusively by canonical inflammasomes and caspase-1. Recent evidence expands this paradigm by linking organellar stress directly to gasdermin-mediated rupture. Specifically, intense mitochondrial depolarization hyperactivates the PINK1-PRKN axis. Clinicians usually view Parkin as a protective neurobiological sentinel. However, sustained Parkin activation unleashes a potent pro-death signaling cascade. Once recruited to depolarized mitochondria, Parkin rapidly ubiquitinates key anti-apoptotic proteins, most notably myeloid cell leukemia-1 (MCL1).

Consequently, accelerated proteasomal clearance of MCL1 destabilizes the delicate balance among Bcl-2 family regulators. Unrestrained BAX and BAK1 then multimerize across the outer mitochondrial membrane, causing extensive permeabilization. As a direct result, cytochrome c leaks into the cytosol, driving apoptosome formation and robust caspase-3 activation. In tissues expressing gasdermin E (GSDME), active caspase-3 specifically cleaves GSDME at its interdomain linker. The liberated amino-terminal domain rapidly integrates into the lipid bilayer of the plasma membrane. Thus, sustained Parkin activation directly drives inflammatory pyroptosis, releasing dangerous damage-associated molecular patterns into the extracellular space.

Bcl-2 Family Dynamics: How MCL1 Degradation Drives BAX Activation

MCL1 functions as a crucial pro-survival guardian within human cells. Under physiological conditions, MCL1 continuously sequesters pro-apoptotic effectors, particularly BAX and BAK1, preventing unprompted pore assembly. However, cellular stressors rapidly destabilize this safeguard. Upon mitochondrial depolarization, activated Parkin recognizes specific lysine residues on MCL1. Parkin then catalyzes polyubiquitin chain formation, tagging MCL1 for immediate destruction by the 26S proteasome. Because MCL1 undergoes accelerated degradation, cellular levels of free pro-apoptotic BH3-only proteins rise precipitously.

Furthermore, the depletion of MCL1 releases active BAX, which translocates directly to the mitochondrial outer membrane. BAX and BAK1 undergo conformational alterations, forming oligomeric pores that breach mitochondrial integrity. Consequently, this membrane permeabilization releases apoptogenic factors, including cytochrome c and SMAC. Although this mitochondrial cascade classically executes apoptosis, high GSDME expression decisively shifts the cellular outcome toward inflammatory lysis. Therefore, Parkin-mediated MCL1 destruction directly dictates cellular fate. Ultimately, this molecular switch determines whether a damaged cell quietly undergoes apoptosis or violently ruptures via pyroptosis.

PTEN-L as a Dual Checkpoint for Mitophagy and Pyroptosis

The discovery of PTEN-L provides a compelling solution to this biological puzzle. PTEN-L represents a translational variant of the classical PTEN tumor suppressor. It possesses an extended N-terminal domain that facilitates membrane localization. Importantly, PTEN-L exhibits potent protein phosphatase activity against phosphorylated Parkin and phosphorylated ubiquitin. By dephosphorylating these molecules, PTEN-L maintains Parkin in its autoinhibited conformational state. Consequently, Parkin fails to accumulate efficiently on depolarized mitochondria, halting the ubiquitination cascade necessary for autophagosome recruitment.

Simultaneously, PTEN-L disrupts the physical interaction between Parkin and its downstream substrate, MCL1. Because PTEN-L preserves MCL1 stability, BAX and BAK1 remain safely sequestered. As a direct result, caspase-3 remains inactive, and GSDME cleavage cannot occur. Thus, PTEN-L executes a dual-checkpoint function within the cell. It concurrently shuts down mitophagy and extinguishes the pyroptotic cascade. Through this coordinated dephosphorylation, PTEN-L ensures that transient mitochondrial fluctuations do not trigger runaway cell destruction. Accordingly, PTEN-L acts as an indispensable rheostat that balances organellar preservation against inflammatory cell death.

Translational Implications for Inflammatory and Degenerative Pathologies

Unraveling this mitochondrial death switch carries immediate translational relevance for clinical practice. In chronic neurodegenerative conditions such as Parkinson disease, dysregulated mitochondrial quality control provokes progressive loss of dopaminergic neurons. While complete loss of PINK1 or PRKN impairs basal clearance, excessive inflammatory signaling exacerbates microglial activation. Therefore, therapeutic agents that enhance PTEN-L activity might protect vulnerable neurons against GSDME-mediated lytic death during acute metabolic stress. Similarly, ischemic reperfusion injury in acute coronary syndromes involves massive mitochondrial depolarization. In these emergency settings, preserving MCL1 stability could substantially reduce infarct size and subsequent cardiac remodeling.

Conversely, in medical oncology, therapy-resistant solid tumors frequently exploit anti-apoptotic pathways by overexpressing MCL1 or PTEN-L. Malignant cells thereby avoid both mitophagic clearance and immunogenic cell death. Pharmacological inhibition of PTEN-L could re-sensitize these recalcitrant tumors. By restoring Parkin phosphorylation, such interventions would promote MCL1 degradation, trigger caspase-3, and induce GSDME-dependent pyroptosis. In addition, this immunogenic demise alerts cytotoxic T lymphocytes and transforms immunologically cold tumors into inflamed targets. Ultimately, targeting the PTEN-L-PRKN interface represents an innovative pharmacological avenue across oncology, cardiology, and neurology.

Frequently Asked Questions

How does PTEN-L inhibit both mitophagy and pyroptosis simultaneously?

PTEN-L acts as an invariant molecular brake on the mitochondrial clearance machinery. Specifically, PTEN-L directly removes the activating phosphate group from Parkin, reversing PINK1-dependent activation. Consequently, inactive Parkin cannot recruit autophagic adapters to initiate mitophagy. Simultaneously, PTEN-L prevents Parkin from targeting MCL1 for ubiquitin-mediated proteasomal degradation. Because MCL1 remains stable, it sequesters pro-apoptotic effectors BAX and BAK1. Therefore, PTEN-L dephosphorylation effectively blunts downstream caspase-3 activation and prevents gasdermin E pore formation, suppressing both pathways concurrently.

Why does the degradation of MCL1 trigger GSDME-mediated pyroptosis instead of apoptosis?

Traditionally, caspase-3 activation drives non-inflammatory apoptotic cell death. However, when cells express high levels of gasdermin E (GSDME), active caspase-3 cleaves GSDME rather than only targeting classic apoptotic substrates. The resulting amino-terminal fragment of GSDME oligomerizes and perforates the plasma membrane, forming large lytic pores. Consequently, the affected cells lose membrane integrity, swell, and release pro-inflammatory cytokines like interleukin-18. Thus, mitochondrial outer membrane permeabilization converts a silent death program into highly inflammatory pyroptosis.

What clinical diseases could benefit from targeting PRKN dephosphorylation?

Modulating this pathway offers substantial therapeutic potential across diverse medical specialties. In neurodegenerative disorders such as Parkinson disease, excessive mitochondrial pyroptosis accelerates neuronal depletion and neuroinflammation. Conversely, in chemoresistant oncological malignancies, malignant clones often suppress GSDME cleavage to evade immunogenic death. Furthermore, acute ischemia-reperfusion injuries in cardiac and renal tissues involve massive mitochondrial depolarization. Therefore, developing small molecules that modulate PTEN-L activity or restore Parkin phosphorylation could either preserve vital tissues or selectively eradicate refractory tumors.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Yan C et al. PRKN dephosphorylation by PTEN-L couples mitophagy inhibition to GSDME pyroptosis suppression. Autophagy. 2026 Oct 20. doi: 10.1080/15548627.2026.2751925. PMID: 42898010.


2. Wang L, et al. PTEN-L is a novel protein phosphatase for ubiquitin dephosphorylation to inhibit PINK1-Parkin-mediated mitophagy. Cell Res. 2018;28(8):787-802.


3. Rogers C, et al. Gasdermin pores permeate and rupture the plasma membrane during pyroptosis. Nat Commun. 2017;8:14157.


4. Eldeeb MA, et al. The Role of PTEN-L in Modulating PINK1-Parkin-Mediated Mitophagy. Neurotox Res. 2022;40(4):1108-1117.